Keyphrases
Denmark
100%
Mycobacterium Tuberculosis (M. tb)
65%
Tuberculosis Patients
54%
Tuberculosis
54%
Chronic Obstructive Pulmonary Disease
45%
Sputum Culture
37%
Chest X-ray
36%
Hydroxychloroquine
36%
Azithromycin
36%
Hospitalized Patients
36%
Copenhagen
26%
Asthma
25%
Latent Tuberculosis Infection
25%
Clot
25%
Genotype
24%
Tuberculosis Disease
22%
Tuberculosis Diagnosis
21%
Tuberculosis Infection
21%
Acute Exacerbation of COPD (AECOPD)
19%
Echocardiographic Predictors
18%
Thromboelastography
18%
Severe Exacerbations
18%
Prospective Cohort Study
18%
Passive Case Finding
18%
Patients with COVID-19
18%
Occupational Tuberculosis
18%
Active Case Finding
18%
Hemostasis
18%
Asylum Seekers
18%
Coronavirus Disease (COVID)
18%
Promethazine
18%
Mobile X-ray
18%
Probe-based
18%
Molecular Assay
18%
Nationwide Register Study
18%
Severe Chronic Obstructive Pulmonary Disease
18%
Tuberculosis Treatment
18%
New Arrivals
18%
Sedating Antihistamines
18%
Asthma Mortality
18%
Diabetes
18%
Randomized Controlled Trial
18%
Placebo
18%
Immunodiagnosis
18%
Randomized Trial
18%
Hepatitis B
18%
Placebo-controlled Trial
18%
Risk of Malignancy
18%
Trial Population
18%
IP-10
18%
Medicine and Dentistry
Tuberculosis
57%
Chronic Obstructive Pulmonary Disease
42%
Sputum Culture
38%
Chest Radiograph
36%
Mycobacterium Tuberculosis
36%
Disease
26%
Retrospective Study
24%
Asthma
24%
Thorax Radiography
21%
Screening
21%
High Risk Population
21%
Thromboelastography
18%
Histamine Antagonist
18%
Blood Stasis
18%
Latent Tuberculosis
18%
Identified Patient
18%
Tuberculosis Treatment
18%
Promethazine
18%
Exercise
18%
Case Finding
18%
Prospective Cohort Study
18%
Diabetes
18%
Dysglycemia
18%
Hydroxychloroquine
18%
Randomized Controlled Trial
18%
COVID-19
18%
Azithromycin
18%
Oral Glucose Tolerance Test
18%
Interferon
18%
Mycobacterium avium
18%
Health Assessment
14%
Sputum
13%
Nucleic Acid Amplification
12%
Prevalence
12%
Blood Glucose
9%
Interferon Gamma Release Assay
8%
Infectious Disease Treatment
7%
Sputum Examination
7%
Melatonin
7%
Dysentery
6%
4 Aminoquinoline Derivative
6%
Walking Distance
6%
Quality of Life
6%
Infection Control
6%
Sensorineural Hearing Loss
6%
Respiratory Medicine
6%
Myasthenia gravis
6%
Interstitial Lung Disease
6%
Intensive Care Unit
6%
Hypersensitivity
6%